Tudriqev Approved After Two FDA Rejections: Contested Evidence Package Clouds $1.3B Sales Projection

Replimune Secures Market Approval for Advanced Melanoma Therapy

Replimune has successfully secured market approval for its oncolytic immunotherapy, RP1, for the treatment of advanced melanoma. This approval follows a challenging regulatory journey that included two prior FDA rejections and a contentious advisory committee meeting, with the final greenlight coming after its scheduled PDUFA date. Analysts project that RP1, to be marketed as Tudriqev, could achieve peak sales of $1.3 billion.

• Replimune's RP1 faced a difficult regulatory path, enduring two rejections from the FDA and a contentious advisory committee meeting before ultimately receiving market approval. The final decision was also delayed beyond its initial PDUFA action date.
• The newly approved oncolytic immunotherapy, RP1, will be sold under the brand name Tudriqev. Industry analysts have expressed optimism regarding its commercial prospects, forecasting potential peak sales to reach $1.3 billion.
• RP1 is an oncolytic immunotherapy specifically indicated for the treatment of advanced melanoma. Its approval marks a significant milestone for Replimune, providing a new therapeutic option for patients battling this severe form of cancer.

Addressing Unmet Needs in Advanced Melanoma Treatment

Advanced melanoma remains one of the most therapeutically complex malignancies, with treatment advances in targeted therapy and immunotherapy offset by persistent challenges in durability, resistance, and tolerability. Despite high initial response rates, a significant proportion of patients ultimately experience disease progression, underscoring the critical unmet needs that continue to drive clinical investigation.

• BRAF/MEK inhibitor resistance: Oncogene-targeted therapy with BRAF and MEK inhibitors yields high initial response rates in BRAF-mutant melanoma, yet median duration of response is approximately one year. Resistance emerges through multiple mechanisms — including mutant BRAF alternative splicing, NRAS mutation, COT (MAP3K8) overexpression, increased BRAF gene amplification, and reactivation of MAPK or PI3K/AKT signaling pathways — with both inter- and intra-patient heterogeneity in resistance profiles further complicating management.

• Immune checkpoint inhibitor resistance: Innate, adaptive, and acquired resistance to immune checkpoint inhibitors remains a major obstacle to durable antitumor activity. Resistance can arise at multiple stages of the tumor immune response, categorized as tumor-derived, T cell-based, or tumor microenvironment-determined mechanisms. Myeloid-derived suppressor cells (MDSCs) contribute to profound immunosuppression in a subset of patients, potentially underpinning non-response to anti-PD-1 therapy.

• Immunosuppressive tumor microenvironment: Tumors exhibiting innate resistance to PD-1 checkpoint antibody therapy are enriched for gene signatures associated with wound healing, epithelial-to-mesenchymal transition, and angiogenesis — collectively termed Innate Anti-PD-1 Resistance Signatures (IPRES) — with TGF-β and VEGFA pathways identified as dominant drivers of these resistance-associated processes.

• Treatment-related toxicities: MAPK pathway-targeted agents are associated with pyrexia, cutaneous toxicities, arthralgias, ocular toxicities, and cardiac events. In triple-combination regimens such as dabrafenib, trametinib, and pembrolizumab, grade 3/4 treatment-related adverse events were observed in 73% of patients — most commonly elevation of liver function tests and pyrexia — frequently requiring drug interruption or discontinuation.

• Challenges in specific disease settings: Patients with leptomeningeal disease represent a particularly difficult-to-treat population with high unmet need. More broadly, tumor heterogeneity and variable clinical responses continue to limit long-term survival outcomes in metastatic melanoma, reinforcing the need for more individualized and adaptive therapeutic strategies.

Tudriqev's Entry into the Evolving Advanced Melanoma Landscape

Over the past five years, the advanced melanoma treatment landscape has been reshaped by landmark data from pivotal clinical trials across two primary therapeutic axes: targeted therapy and immune checkpoint inhibition. BRAF/MEK inhibitor combinations — vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib — have solidified their role as standard-of-care options for BRAF V600-mutant disease. Real-world confirmation of these regimens has followed, with the COMBI-r study (n=472) reporting a median progression-free survival of 8.3 months and median overall survival of 18.3 months with dabrafenib plus trametinib under routine clinical conditions, closely mirroring results from the foundational phase III trials. In parallel, long-term follow-up from CheckMate 067 (6.5 years) has substantially reinforced the role of dual checkpoint blockade: the nivolumab plus ipilimumab combination achieved a median overall survival of 72.1 months, with 6.5-year OS rates of 57% and 46% in BRAF-mutant and BRAF-wild-type populations, respectively — benchmarks that have materially influenced how first-line sequencing decisions are now approached.

The most consequential recent addition to the treatment armamentarium has been the LAG-3/PD-1 dual blockade strategy. The RELATIVITY-047 trial demonstrated that nivolumab plus relatlimab extended median progression-free survival to 10.1 months versus 4.6 months with nivolumab monotherapy (HR 0.75; P=0.006), leading to regulatory approval by both the FDA and EMA. Critically, indirect treatment comparisons using patient-level data from RELATIVITY-047 and CheckMate 067 suggest comparable efficacy to nivolumab plus ipilimumab in the overall population, but with a substantially improved safety profile: grade 3–4 treatment-related adverse events occurred in 23% versus 61% of patients, and treatment-related discontinuations in 17% versus 41%, respectively. These data have prompted a re-evaluation of the established first-line immunotherapy hierarchy, with current NCCN guidelines now listing nivolumab plus relatlimab alongside nivolumab plus ipilimumab and pembrolizumab as preferred first-line options regardless of BRAF mutation status.

Beyond the metastatic setting, the field has increasingly turned its attention to neoadjuvant and perioperative strategies in resectable stage III disease. Emerging evidence demonstrates improved recurrence-free and distant metastasis-free survival with neoadjuvant systemic therapy compared to adjuvant-only approaches, with pathological response emerging as a robust prognostic surrogate. The NeoTrio trial, conducted in resectable stage III BRAF-mutant melanoma, reported pathological response rates of 55% with pembrolizumab monotherapy, 50% with sequential BRAF/MEK inhibition followed by pembrolizumab, and 80% with concurrent triple therapy — yet recurrences following major pathological response were more frequent in the targeted therapy-containing arms, raising important questions about response durability when targeted agents are combined with neoadjuvant immunotherapy. Taken together, these data underscore a rapidly evolving landscape in which treatment decisions are increasingly nuanced by mutation status, disease stage, metastatic burden, and now, the relative safety-efficacy trade-offs across a broadening set of approved combination regimens.